Arrowhead ResearchARWR
ARWR
About: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Employees: 525
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
17% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $10.1M
12% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 41
1.49% more ownership
Funds ownership: 78.85% [Q3] → 80.34% (+1.49%) [Q4]
5% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 86
0% more funds holding
Funds holding: 270 [Q3] → 271 (+1) [Q4]
1% less capital invested
Capital invested by funds: $1.9B [Q3] → $1.88B (-$19M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
152%
upside
Avg. target
$55
265%
upside
High target
$80
431%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Mayank Mamtani 10% 1-year accuracy 2 / 20 met price target | 152%upside $38 | Buy Reiterated | 14 Feb 2025 |
HC Wainwright & Co. Patrick Trucchio 23% 1-year accuracy 42 / 185 met price target | 431%upside $80 | Buy Reiterated | 12 Feb 2025 |
RBC Capital Luca Issi 15% 1-year accuracy 8 / 53 met price target | 179%upside $42 | Outperform Reiterated | 11 Feb 2025 |
Chardan Capital Keay Nakae 14% 1-year accuracy 10 / 69 met price target | 298%upside $60 | Buy Maintained | 11 Feb 2025 |
Financial journalist opinion
Based on 7 articles about ARWR published over the past 30 days
Neutral
Business Wire
3 days ago
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025. Select Phase 1/2 Study Results Patients with IgA nephrop.
Neutral
Business Wire
1 week ago
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass comp.
Neutral
Business Wire
1 week ago
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We'll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS). FCS is an ultra-rare genetic disorder that signi.
Neutral
Business Wire
2 weeks ago
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025 in Banff, AB, Canada. ARO-ALK7 is the first RNAi-based therapy to directly targe.
Positive
Seeking Alpha
3 weeks ago
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent.
Positive
Market Watch
3 weeks ago
20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'
The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries.
Neutral
Seeking Alpha
1 month ago
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital David Lebowitz - Citi Jasmine Fels - UBS Maury Raycroft - Jefferies Edward Tenthoff - PSC Patrick Trucchio - H.C. Wainwright Mayank Mamtani - B.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. “During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which w.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Summary Financial Terms Upon closing, Arrowhead receives a $500 milli.
Neutral
PRNewsWire
1 month ago
Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600
NEW YORK , Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE: GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE: B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE: APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions.
Charts implemented using Lightweight Charts™